<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><meta name="description" content="The function optimal_multiple_normal of the drugdevelopR package enables planning of phase II/III drug development programs with optimal sample size allocation and go/no-go decision rules (Preussler et. al, 2019).  (planning is also possible via user friendly R Shiny App: multiarm). Fast coputing is enabled by parallel programming."><title>Optimal phase II/III drug development planning for programs with multiple endpoints — optimal_multiple_normal • drugdevelopR</title><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.1.3/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.1.3/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous"><!-- bootstrap-toc --><script src="https://cdn.rawgit.com/afeld/bootstrap-toc/v1.0.1/dist/bootstrap-toc.min.js"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Optimal phase II/III drug development planning for programs with multiple endpoints — optimal_multiple_normal"><meta property="og:description" content="The function optimal_multiple_normal of the drugdevelopR package enables planning of phase II/III drug development programs with optimal sample size allocation and go/no-go decision rules (Preussler et. al, 2019).  (planning is also possible via user friendly R Shiny App: multiarm). Fast coputing is enabled by parallel programming."><!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]--></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">drugdevelopR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.1.0</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="active nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="nav-item dropdown">
  <a href="#" class="nav-link dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-expanded="false" aria-haspopup="true" id="dropdown-articles">Articles</a>
  <div class="dropdown-menu" aria-labelledby="dropdown-articles">
    <a class="dropdown-item" href="../articles/introduction-to-drugdevelopR.html">Introduction to planning phase II and phase III trials with drugdevelopR</a>
  </div>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul><form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off"></form>

      <ul class="navbar-nav"><li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/Sterniii3/drugdevelopR/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul></div>

    
  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="" class="logo" alt=""><h1>Optimal phase II/III drug development planning for programs with multiple endpoints</h1>
      <small class="dont-index">Source: <a href="https://github.com/Sterniii3/drugdevelopR/blob/HEAD/R/optimal_multiple_normal.R" class="external-link"><code>R/optimal_multiple_normal.R</code></a></small>
      <div class="d-none name"><code>optimal_multiple_normal.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p>The function <code>optimal_multiple_normal</code> of the drugdevelopR package enables planning of phase II/III drug development programs with optimal sample size allocation and go/no-go decision rules (Preussler et. al, 2019).  (planning is also possible via user friendly R Shiny App: <a href="https://web.imbi.uni-heidelberg.de/multiarm/" class="external-link">multiarm</a>). Fast coputing is enabled by parallel programming.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-usage">Usage<a class="anchor" aria-label="anchor" href="#ref-usage"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="fu">optimal_multiple_normal</span><span class="op">(</span></span>
<span>  <span class="va">Delta1</span>,</span>
<span>  <span class="va">Delta2</span>,</span>
<span>  <span class="va">in1</span>,</span>
<span>  <span class="va">in2</span>,</span>
<span>  <span class="va">sigma1</span>,</span>
<span>  <span class="va">sigma2</span>,</span>
<span>  <span class="va">n2min</span>,</span>
<span>  <span class="va">n2max</span>,</span>
<span>  <span class="va">stepn2</span>,</span>
<span>  <span class="va">kappamin</span>,</span>
<span>  <span class="va">kappamax</span>,</span>
<span>  <span class="va">stepkappa</span>,</span>
<span>  <span class="va">alpha</span>,</span>
<span>  <span class="va">beta</span>,</span>
<span>  <span class="va">c2</span>,</span>
<span>  <span class="va">c3</span>,</span>
<span>  <span class="va">c02</span>,</span>
<span>  <span class="va">c03</span>,</span>
<span>  K <span class="op">=</span> <span class="cn">Inf</span>,</span>
<span>  N <span class="op">=</span> <span class="cn">Inf</span>,</span>
<span>  S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,</span>
<span>  steps1 <span class="op">=</span> <span class="fl">0</span>,</span>
<span>  stepm1 <span class="op">=</span> <span class="fl">0.5</span>,</span>
<span>  stepl1 <span class="op">=</span> <span class="fl">0.8</span>,</span>
<span>  <span class="va">b1</span>,</span>
<span>  <span class="va">b2</span>,</span>
<span>  <span class="va">b3</span>,</span>
<span>  <span class="va">rho</span>,</span>
<span>  <span class="va">fixed</span>,</span>
<span>  relaxed <span class="op">=</span> <span class="cn">FALSE</span>,</span>
<span>  num_cl <span class="op">=</span> <span class="fl">1</span></span>
<span><span class="op">)</span></span></code></pre></div>
    </div>

    <div class="section level2">
    <h2 id="arguments">Arguments<a class="anchor" aria-label="anchor" href="#arguments"></a></h2>
    <dl><dt>Delta1</dt>
<dd><p>assumed true treatment effect on HR scale for treatment 1</p></dd>


<dt>Delta2</dt>
<dd><p>assumed true treatment effect on HR scale for treatment 2</p></dd>


<dt>in1</dt>
<dd><p>amount of information for Delta1 in terms of number of events</p></dd>


<dt>in2</dt>
<dd><p>amount of information for Delta2 in terms of number of events</p></dd>


<dt>sigma1</dt>
<dd><p>variance of endpoint 1</p></dd>


<dt>sigma2</dt>
<dd><p>variance of endpoint 1</p></dd>


<dt>n2min</dt>
<dd><p>minimal total sample size in phase II, must be divisible by 3</p></dd>


<dt>n2max</dt>
<dd><p>maximal total sample size in phase II, must be divisible by 3</p></dd>


<dt>stepn2</dt>
<dd><p>stepsize for the optimization over n2, must be divisible by 3</p></dd>


<dt>kappamin</dt>
<dd><p>minimal threshold value for the go/no-go decision rule</p></dd>


<dt>kappamax</dt>
<dd><p>maximal threshold value for the go/no-go decision rule</p></dd>


<dt>stepkappa</dt>
<dd><p>stepsize for the optimization over HRgo</p></dd>


<dt>alpha</dt>
<dd><p>one-sided significance level/ family wise error rate</p></dd>


<dt>beta</dt>
<dd><p>1-beta (any-pair) power for calculation of the number of events for phase III</p></dd>


<dt>c2</dt>
<dd><p>variable per-patient cost for phase II</p></dd>


<dt>c3</dt>
<dd><p>variable per-patient cost for phase III</p></dd>


<dt>c02</dt>
<dd><p>fixed cost for phase II</p></dd>


<dt>c03</dt>
<dd><p>fixed cost for phase III</p></dd>


<dt>K</dt>
<dd><p>constraint on the costs of the program, default: Inf, e.g. no constraint</p></dd>


<dt>N</dt>
<dd><p>constraint on the total expected sample size of the program, default: Inf, e.g. no constraint</p></dd>


<dt>S</dt>
<dd><p>constraint on the expected probability of a successful program, default: -Inf, e.g. no constraint</p></dd>


<dt>steps1</dt>
<dd><p>lower boundary for effect size category "small" in HR scale, default: 1</p></dd>


<dt>stepm1</dt>
<dd><p>lower boundary for effect size category "medium" in HR scale = upper boundary for effect size category "small" in HR scale, default: 0.95</p></dd>


<dt>stepl1</dt>
<dd><p>lower boundary for effect size category "large" in HR scale = upper boundary for effect size category "medium" in HR scale, default: 0.85</p></dd>


<dt>b1</dt>
<dd><p>expected gain for effect size category "small"</p></dd>


<dt>b2</dt>
<dd><p>expected gain for effect size category "medium"</p></dd>


<dt>b3</dt>
<dd><p>expected gain for effect size category "large"</p></dd>


<dt>rho</dt>
<dd><p>correlation between the two endpoints</p></dd>


<dt>fixed</dt>
<dd><p>assumed fixed treatment effect</p></dd>


<dt>relaxed</dt>
<dd><p>relaxed or strict decision rule</p></dd>


<dt>num_cl</dt>
<dd><p>number of clusters used for parallel computing, default: 1</p></dd>

</dl></div>
    <div class="section level2">
    <h2 id="value">Value<a class="anchor" aria-label="anchor" href="#value"></a></h2>
    

<p>The output of the function <code><a href="optimal_multiple_tte.html">optimal_multiple_tte</a></code> is a data.frame containing the optimization results:</p><dl><dt>u</dt>
<dd><p>maximal expected utility</p></dd>

<dt>Kappa</dt>
<dd><p>optimal threshold value for the decision rule to go to phase III</p></dd>

<dt>n2</dt>
<dd><p>total sample size for phase II</p></dd>

<dt>n3</dt>
<dd><p>total sample size for phase III; rounded to the next even natural number</p></dd>

<dt>n</dt>
<dd><p>total sample size in the program; n = n2 + n3</p></dd>

<dt>K</dt>
<dd><p>maximal costs of the program</p></dd>

<dt>pgo</dt>
<dd><p>probability to go to phase III</p></dd>

<dt>sProg</dt>
<dd><p>probability of a successful program</p></dd>

<dt>sProg1</dt>
<dd><p>probability of a successful program with "small" treatment effect in Phase III</p></dd>

<dt>sProg2</dt>
<dd><p>probability of a successful program with "medium" treatment effect in Phase III</p></dd>

<dt>sProg3</dt>
<dd><p>probability of a successful program with "large" treatment effect in Phase III</p></dd>

<dt>K2</dt>
<dd><p>expected costs for phase II</p></dd>

<dt>K3</dt>
<dd><p>expected costs for phase III</p></dd>


</dl><p>and further input parameters.</p>


<p>Taking cat(comment()) of the data.frame object lists the used optimization sequences, start and finish date of the optimization procedure.
@examples
#res &lt;- optimal_multiple_normal(Delta1 = 0.75, Delta2 = 0.80,    # define assumed true HRs and control arm event ratein1=300, in2=600, sigma1 = 8, sigma2= 12,n2min = 30, n2max = 90, stepn2 = 6,                    # define optimization set for n2kappamin = 0.7, kappamax = 0.9, stepkappa = 0.05,         # define optimization set for HRgoalpha = 0.05, beta = 0.1,                              # drug development planning parametersc2 = 0.75, c3 = 1, c02 = 100, c03 = 150,               # define fixed and variable costs for phase II and IIIK = Inf, N = Inf, S = -Inf,                            # set maximal costs/ expected sample size for the program or minimal expected probability of a successful programsteps1 = 0,                                            # define lower boundary for "small"stepm1 = 0.5,                                          # "medium"stepl1 = 0.88,                                         # and "large" treatment effect size categories as proposed by IQWiG (2016)b1 = 1000, b2 = 2000, b3 = 3000,                       # define expected benefit for a "small", "medium" and "large" treatment effectrho = 0.5, relaxed = TRUE,                             # relaxed "TRUE"fixed = TRUE,                                          #   treatment effectnum_cl = 1)                                            # set number of cores used for parallelized computing (check maximum number possible with detectCores())</p>


<p>#res
#cat(comment(res))                                        # displays the optimization sequence, start and finish date of the optimization procedure.</p>
    </div>
    <div class="section level2">
    <h2 id="drugdevelopr-functions">drugdevelopR functions<a class="anchor" aria-label="anchor" href="#drugdevelopr-functions"></a></h2>
    

<p>The drugdevelopR package provides the functions</p><ul><li><p><code><a href="optimal_tte.html">optimal_tte</a></code>,</p></li>
<li><p><code><a href="optimal_binary.html">optimal_binary</a></code> and</p></li>
<li><p><code><a href="optimal_normal.html">optimal_normal</a></code></p></li>
</ul><p>to plan optimal phase II/III drug development programs with</p><ul><li><p>time-to-event (treatment effect measured by hazard ratio (HR)),</p></li>
<li><p>binary (treatment effect measured by risk ratio (RR)) or</p></li>
<li><p>normally distributed (treatment effect measured by standardized difference in means (Delta))</p></li>
</ul><p>endpoint, where the treatment effect is modelled by a <a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">prior</a>. Optimal phase II/III drug development planning with fixed treatment effects can be done with the help of the R Shiny application <a href="https://web.imbi.uni-heidelberg.de/basic/" class="external-link">basic</a>. Extensions are</p><ul><li><p>optimal planning of programs including methods for discounting of phase II results (function: <code><a href="optimal_bias.html">optimal_bias</a></code>, App: <a href="https://web.imbi.uni-heidelberg.de/bias/" class="external-link">bias</a>),</p></li>
<li><p>optimal planning of programs with several phase III trials (function: <code><a href="optimal_multitrial.html">optimal_multitrial</a></code>, App: <a href="https://web.imbi.uni-heidelberg.de/multitrial/" class="external-link">multitrial</a>) and</p></li>
<li><p>optimal planning of programs with multiple arms (function: <code><a href="optimal_multiarm.html">optimal_multiarm</a></code>, App: <a href="https://web.imbi.uni-heidelberg.de/multiarm/" class="external-link">multiarm</a>).</p></li>
</ul></div>
    <div class="section level2">
    <h2 id="references">References<a class="anchor" aria-label="anchor" href="#references"></a></h2>
    <p>Preussler, S., Kirchner, M., Goette, H., Kieser, M. (2019). Optimal Designs for Multi-Arm Phase II/III Drug Development Programs. Submitted to peer-review journal.</p>
<p>IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available at <a href="https://www.iqwig.de/de/methoden/methodenpapier.3020.html" class="external-link">https://www.iqwig.de/de/methoden/methodenpapier.3020.html</a>, assessed last 15.05.19.</p>
    </div>
    <div class="section level2">
    <h2 id="last-edited-by">Last Edited By<a class="anchor" aria-label="anchor" href="#last-edited-by"></a></h2>
    <p>Johannes Cepicka</p>
    </div>
    <div class="section level2">
    <h2 id="last-edit-date">Last Edit Date<a class="anchor" aria-label="anchor" href="#last-edit-date"></a></h2>
    <p>2022-04-23</p>
    </div>

  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p></p><p>Developed by Stella Preussler.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p><p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.6.</p>
</div>

    </footer></div>

  

  

  </body></html>

